A Concept-to-Commercialization Viral Vector CDMO

Andelyn Biosciences is a gene therapy CDMO with deep expertise and experience in the development and production of viral vectors. With its origins including 20+ years of experience manufacturing viral vectors, Andelyn’s scientific expertise for development and characterization of gene therapies has led to GMP material being produced for over 75+ worldwide clinical trials and 450+ cGMP clinical batches. We support companies developing curative gene therapies for rare and prevalent diseases with plasmid manufacturing, process development, and GMP manufacturing capacity for both adherent and suspension processes up to 2,000L. An advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of our clients' innovative therapies.

Play video

We support clients through all phases of development and commercialization.

Our Name

The name “Andelyn” was chosen to pay tribute to two brave young patients that participated in pivotal clinical trials that make today’s gene therapies possible.

Updates from Andelyn

News & Media

June 11, 2024

UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

News

May 23, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, May 23, 2024 – Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and...

News

March 25, 2024

Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency

COLUMBUS, OH, March 25, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

News

February 28, 2024

Andelyn Biosciences Selected as Viral Vector Manufacturing Partner for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership® (AMP®) Bespoke Gene Therapy Consortium (BGTC)

COLUMBUS, OH, February 28, 2024 – Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and...

Our Employees Fuel Our Success

Andelyn is made up of an Inspired, Innovative and Compassionate team that contribute towards a rich company culture. We are always looking for great people who want to do great things.